Zacks Research Comments on Halozyme Therapeutics, Inc.’s FY2026 Earnings (NASDAQ:HALO)

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Analysts at Zacks Research boosted their FY2026 earnings per share (EPS) estimates for shares of Halozyme Therapeutics in a research report issued to clients and investors on Monday, April 22nd. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will earn $5.16 per share for the year, up from their prior forecast of $5.08. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $3.45 per share.

A number of other equities research analysts have also recently weighed in on HALO. StockNews.com upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, February 23rd. TheStreet cut Halozyme Therapeutics from a “b-” rating to a “c+” rating in a research note on Monday, January 22nd. Benchmark reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Halozyme Therapeutics in a report on Tuesday, April 16th. TD Cowen began coverage on Halozyme Therapeutics in a report on Thursday, February 29th. They issued an “outperform” rating and a $54.00 price objective on the stock. Finally, The Goldman Sachs Group decreased their price objective on Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating on the stock in a report on Thursday, January 18th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $53.29.

Halozyme Therapeutics Stock Up 0.7 %

HALO opened at $38.97 on Wednesday. Halozyme Therapeutics has a 1-year low of $29.85 and a 1-year high of $45.00. The stock’s fifty day simple moving average is $39.62 and its 200 day simple moving average is $37.78. The company has a current ratio of 6.64, a quick ratio of 5.50 and a debt-to-equity ratio of 17.89. The stock has a market cap of $4.95 billion, a PE ratio of 18.47, a price-to-earnings-growth ratio of 0.45 and a beta of 1.25.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. The company had revenue of $230.04 million for the quarter, compared to the consensus estimate of $235.25 million.

Insider Transactions at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction on Wednesday, April 17th. The stock was sold at an average price of $38.49, for a total transaction of $384,900.00. Following the sale, the senior vice president now directly owns 168,176 shares of the company’s stock, valued at approximately $6,473,094.24. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In the last three months, insiders have sold 30,000 shares of company stock valued at $1,196,800. 2.70% of the stock is owned by corporate insiders.

Institutional Trading of Halozyme Therapeutics

Large investors have recently modified their holdings of the stock. Rise Advisors LLC acquired a new stake in Halozyme Therapeutics in the first quarter valued at about $25,000. Principal Securities Inc. acquired a new stake in Halozyme Therapeutics in the fourth quarter valued at about $34,000. First Horizon Advisors Inc. boosted its stake in Halozyme Therapeutics by 24.5% in the fourth quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 293 shares in the last quarter. Parkside Financial Bank & Trust acquired a new stake in Halozyme Therapeutics in the fourth quarter valued at about $64,000. Finally, Headlands Technologies LLC boosted its stake in Halozyme Therapeutics by 1,068.2% in the fourth quarter. Headlands Technologies LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $65,000 after buying an additional 1,613 shares in the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.